Carisma Therapeutics Inc. is a biopharmaceutical company engaged in the development of innovative cellular therapies. Its primary focus is on advancing cutting-edge treatments designed to harness the body’s innate immune system to combat cancer. By utilizing chimeric antigen receptor macrophages (CAR-M), Carisma is pioneering a new approach in the field of immunotherapy, offering potentially transformative solutions by directly targeting and eliminating malignant cells. This focus positions the company at the forefront of oncology therapeutics, with significant impacts anticipated in the biotechnology and healthcare sectors. Headquartered in the healthcare research hub of Philadelphia, Carisma Therapeutics leverages strategic partnerships and collaborations to enhance its research capabilities and expand its development pipeline. As a significant player in the ongoing evolution of cancer treatment modalities, Carisma Therapeutics contributes to the broader market dynamics through its emphasis on innovation and patient-centric solutions.